Logo image of TPTX

TURNING POINT THERAPEUTICS I (TPTX) Stock Fundamental Analysis

NASDAQ:TPTX - Nasdaq - US90041T1088 - Common Stock - Currency: USD

76.01  +0.52 (+0.69%)

After market: 75.99 -0.02 (-0.03%)

Fundamental Rating

2

Overall TPTX gets a fundamental rating of 2 out of 10. We evaluated TPTX against 571 industry peers in the Biotechnology industry. The financial health of TPTX is average, but there are quite some concerns on its profitability. TPTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TPTX had negative earnings in the past year.
TPTX Yearly Net Income VS EBIT VS OCF VS FCFTPTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 -50M -100M -150M -200M

1.2 Ratios

Industry RankSector Rank
ROA -40.59%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TPTX Yearly ROA, ROE, ROICTPTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 -10 -20 -30 -40

1.3 Margins

The Operating Margin and Gross Margin are not available for TPTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -33959.03%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TPTX Yearly Profit, Operating, Gross MarginsTPTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 -200 -400 -600

More info and screens

6

2. Health

2.1 Basic Checks

TPTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
TPTX has more shares outstanding than it did 1 year ago.
There is no outstanding debt for TPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TPTX Yearly Shares OutstandingTPTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 10M 20M 30M 40M
TPTX Yearly Total Debt VS Total AssetsTPTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 200M 400M 600M 800M 1B

2.2 Solvency

TPTX has an Altman-Z score of 43.61. This indicates that TPTX is financially healthy and has little risk of bankruptcy at the moment.
There is no outstanding debt for TPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 43.61
ROIC/WACCN/A
WACC9.48%
TPTX Yearly LT Debt VS Equity VS FCFTPTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 0 200M 400M 600M 800M 1B

2.3 Liquidity

TPTX has a Current Ratio of 16.83. This indicates that TPTX is financially healthy and has no problem in meeting its short term obligations.
TPTX has a Quick Ratio of 16.83. This indicates that TPTX is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 16.83
Quick Ratio 16.83
TPTX Yearly Current Assets VS Current LiabilitesTPTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 200M 400M 600M 800M 1B

More info and screens

2

3. Growth

3.1 Past

The earnings per share for TPTX have decreased strongly by -56.03% in the last year.
The Revenue for TPTX has decreased by -98.18% in the past year. This is quite bad
EPS 1Y (TTM)-56.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-116.54%
Revenue 1Y (TTM)-98.18%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-97.7%

3.2 Future

TPTX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.71% yearly.
TPTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 111.81% yearly.
EPS Next Y-43.06%
EPS Next 2Y-23.87%
EPS Next 3Y-3.45%
EPS Next 5Y-5.71%
Revenue Next Year-78.46%
Revenue Next 2Y10.77%
Revenue Next 3Y90.91%
Revenue Next 5Y111.82%

3.3 Evolution

TPTX Yearly Revenue VS EstimatesTPTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
TPTX Yearly EPS VS EstimatesTPTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TPTX. In the last year negative earnings were reported.
Also next year TPTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TPTX Price Earnings VS Forward Price EarningsTPTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -8.62
TPTX Per share dataTPTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

A cheap valuation may be justified as TPTX's earnings are expected to decrease with -3.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.87%
EPS Next 3Y-3.45%

More info and screens

0

5. Dividend

5.1 Amount

TPTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TURNING POINT THERAPEUTICS I

NASDAQ:TPTX (8/16/2022, 8:02:36 PM)

After market: 75.99 -0.02 (-0.03%)

76.01

+0.52 (+0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2022-08-08
Earnings (Next)11-07 2022-11-07
Inst Owners1.24%
Inst Owner Change0%
Ins Owners4.58%
Ins Owner Change0%
Market Cap3.78B
Analysts72
Price Target74.9 (-1.46%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3745.17
P/FCF N/A
P/OCF N/A
P/B 4.76
P/tB N/A
EV/EBITDA -8.62
EPS(TTM)-4.79
EYN/A
EPS(NY)-7.35
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.02
BVpS15.97
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.59%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -33959.03%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.83
Quick Ratio 16.83
Altman-Z 43.61
F-Score2
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-116.54%
EPS Next Y-43.06%
EPS Next 2Y-23.87%
EPS Next 3Y-3.45%
EPS Next 5Y-5.71%
Revenue 1Y (TTM)-98.18%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-97.7%
Revenue Next Year-78.46%
Revenue Next 2Y10.77%
Revenue Next 3Y90.91%
Revenue Next 5Y111.82%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A